187 related articles for article (PubMed ID: 29546323)
1. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
[TBL] [Abstract][Full Text] [Related]
3. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer.
Mao J; Ma L; Shen Y; Zhu K; Zhang R; Xi W; Ruan Z; Luo C; Chen Z; Xi X; Chen S
Cell Death Dis; 2018 Sep; 9(10):963. PubMed ID: 30237564
[TBL] [Abstract][Full Text] [Related]
4. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82.
Yang CH; Chou HC; Fu YN; Yeh CL; Cheng HW; Chang IC; Liu KJ; Chang GC; Tsai TF; Tsai SF; Liu HP; Wu YC; Chen YT; Huang SF; Chen YR
Biochim Biophys Acta; 2015 Jul; 1852(7):1540-9. PubMed ID: 25912735
[TBL] [Abstract][Full Text] [Related]
5. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
Della Corte CM; Bellevicine C; Vicidomini G; Vitagliano D; Malapelle U; Accardo M; Fabozzi A; Fiorelli A; Fasano M; Papaccio F; Martinelli E; Troiani T; Troncone G; Santini M; Bianco R; Ciardiello F; Morgillo F
Clin Cancer Res; 2015 Oct; 21(20):4686-97. PubMed ID: 26124204
[TBL] [Abstract][Full Text] [Related]
6. MET amplification increases the metastatic spread of EGFR-mutated NSCLC.
Baldacci S; Kherrouche Z; Cockenpot V; Stoven L; Copin MC; Werkmeister E; Marchand N; Kyheng M; Tulasne D; Cortot AB
Lung Cancer; 2018 Nov; 125():57-67. PubMed ID: 30429039
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Shien K; Ueno T; Tsukuda K; Soh J; Suda K; Kubo T; Furukawa M; Muraoka T; Maki Y; Tanaka N; Yamamoto H; Kiura K; Mitsudomi T; Toyooka S; Miyoshi S
Clin Lung Cancer; 2012 Nov; 13(6):488-93. PubMed ID: 22503506
[TBL] [Abstract][Full Text] [Related]
9. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Zhang X; Song Q; Wei C; Qu J
Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
[TBL] [Abstract][Full Text] [Related]
10. LRIG1 opposes epithelial-to-mesenchymal transition and inhibits invasion of basal-like breast cancer cells.
Yokdang N; Hatakeyama J; Wald JH; Simion C; Tellez JD; Chang DZ; Swamynathan MM; Chen M; Murphy WJ; Carraway Iii KL; Sweeney C
Oncogene; 2016 Jun; 35(22):2932-47. PubMed ID: 26387542
[TBL] [Abstract][Full Text] [Related]
11. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
[TBL] [Abstract][Full Text] [Related]
12. Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.
Terashima M; Togashi Y; Sato K; Mizuuchi H; Sakai K; Suda K; Nakamura Y; Banno E; Hayashi H; De Velasco MA; Fujita Y; Tomida S; Mitsudomi T; Nishio K
Clin Cancer Res; 2016 Jul; 22(14):3663-71. PubMed ID: 26826182
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
[TBL] [Abstract][Full Text] [Related]
14. TTF-1/Nkx2.1 functional connection with mutated EGFR relies on LRIG1 and β-catenin pathways in lung cancer cells.
Zamboni M; Civitareale D
Biochem Biophys Res Commun; 2018 Nov; 505(4):1027-1031. PubMed ID: 30314701
[TBL] [Abstract][Full Text] [Related]
15. Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line.
Tsukumo Y; Naito M; Suzuki T
PLoS One; 2020; 15(3):e0229712. PubMed ID: 32130260
[TBL] [Abstract][Full Text] [Related]
16. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.
Greve G; Schiffmann I; Pfeifer D; Pantic M; Schüler J; Lübbert M
BMC Cancer; 2015 Dec; 15():947. PubMed ID: 26675484
[TBL] [Abstract][Full Text] [Related]
17. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
Li W; Zhou Y
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30487162
[TBL] [Abstract][Full Text] [Related]
18. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
Yang Z; Zhang SL; Hu X; Tam KY
Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
[TBL] [Abstract][Full Text] [Related]
20. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
